AURE vs RVPH Comparison

Aurelion Inc is engaged in providing private wealth management and asset management services to high-net-worth and ultra-high-net-worth individuals by identifying and purchasing well-matched wealth management products offered by third-party providers. Its subsidiary operates a wealth management business that works with licensed product brokers in Hong Kong, currently consisting solely of insurance brokers distributing insurance products, and assists in customizing wealth management investment portfolios for clients. The Company generates revenue for its subsidiaries' wealth management business from product brokers in the form of referral fees, which are calculated based on the value of wealth management products purchased by clients from such brokers.

Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease and Parkinson's disease psychosis and its other drug candidate is RP1208.